Houston home builder stays ahead of the competition by incorporating new technologies

home tech

Within the next five years, Frankel believes that the technology they are using will evolve even more, perhaps to include holographic 3D models of homes they hope to build for their clients. Getty Images

For Frankel Building Group, the evolution of technology in the real estate and construction world was the next logical step in creating a sustainable and viable company. By incorporating technology into its client-based custom design and build firm through the use of a personal app and 3D renderings, co-president and principal Scott Frankel said Frankel Building Group is years ahead of the rest of the competition.

Frankel, who runs the company alongside his brother Kevin, described it as "a responsibility to do better and to show more."

"Our company, when I got here, was politely a little bit in the stone ages," Scott Frankel tells InnovationMap. "In order to be a customer facing business, and in order to compete in the market, we have learned to be a very technology-forward business. I would say out of every custom builder in the country, we are probably the most technology-reliant builder out there. That's a good thing."

The building group, which was started by 30 years ago by Scott and Kevin's father Jim, uses technology in every aspect of its projects.

Five to 10 years ago, builders would have to import designs into AutoCAD, a software that allows builders, engineers and architects to see their drawings in 3D form. Those AutoCAD drawings would then be printed and given to the homebuyer.

At Frankel Building Group, clients are able to login to an online portal that allows them to see every communication between them and the Frankel team, as well as building plans, updates, and digital 3D renderings of their homes. Everything from estimates to the latest updates from their assigned project manager are available to homebuyers from their phone.

"Our clients want that access," Frankel said. "If they don't get that access, they are going to be left with more questions than answers."

Frankel believes that they are only doing what the clients expect from a custom homebuilder: increasing communication through every means possible to make sure the client is satisfied with what the builder is doing.

"My brother and I are not huge technology guys," Frankel said. "We didn't come from this as framers who became custom builders. We came from a family that built custom homes and (using technology) only makes logical sense because it's something that makes it better. It's kind of like when you're banking with Chase and they came out with online banking — it just makes it better."

Within the next five years, Frankel believes that the technology they are using will evolve even more, perhaps to include holographic 3D models of homes they hope to build for their clients.

But, for now, Frankel Building Group is focused on growing their business one day at a time.

"Our focus is people in Houston who want to design and build that home for them on their property," Frankel said. "We just want to make sure we're putting the best product out there."

A 3-D printed home could be built in 48 hours for only $10,000. Photo courtesy of ICON Build

Texas startup receives $9M to build affordable 3-D printed houses

High-tech homes

In the not-too-distant future, a Texas company's 3-D printed homes will be popping up across the world for a fraction of the cost of traditional homes.

"It's our mission at ICON to reimagine the approach to homebuilding and construction and make affordable, dignified housing available to everyone throughout the world," says Jason Ballard, co-founder and CEO of Austin-based ICON LLC. "We're in the middle of a global housing crisis, and making old approaches a little better is not solving the problem."

The 3-D printed homes startup just raked in $9 million in seed funding from a host of investors, including Fort Worth-based homebuilding giant D.R. Horton; Vulcan Capital, a Seattle investment firm launched by Microsoft billionaire Paul Allen, who died October 15; Austin startup accelerator Capital Factory; Austin real estate developer Cielo Property Group; and San Francisco venture capital firm Oakhouse Partners, which is the lead investor.

At this point, ICON executives aren't sure when their homes will be popping up around town. However, Ballard tells CultureMap, "serious conversations" are underway about bringing these homes to Austin and other places around the world.

In March, ICON reaped tons of press when it unveiled a 350-square-foot 3-D home at SXSW — the first home of its kind to receive a construction permit in the U.S. At the time, ICON executives said the home — constructed of concrete and printed in less than 48 hours by 3-D printing robots — cost less than $10,000. By contrast, the median price in September 2018 of a single-family home in the Austin metro area was $302,250.

ICON's first batch of homes is planned for a project in impoverished El Salvador that's being developed in conjunction with New Story, a San Francisco nonprofit that seeks to eradicate homelessness. The first homes there are scheduled to be printed next year.

ICON is targeting a per-home cost of $4,000 in El Salvador. Relying on technology upgrades, ICON hopes to create each 3-D home in less than 24 hours.

"While prices to print homes will vary from country to country and state to state," Ballard says, "the big takeaway is that downloading and printing a home has the potential to cost half of standard construction costs."

Homes at the development in El Salvador will measure 600 to 800 square feet — around the size of a typical one-bedroom apartment. Eventually, ICON aims to print homes in the 1,500- to 2,000-square-foot range.

Among the advantages of 3-D printed homes cited by ICON are:

  • Speedy construction
  • No manual labor
  • Little generation of leftover construction materials
  • "Tremendous" design freedom

There's a positive environmental impact with this construction process as well.

"Conventional construction is slow, fragmented, wasteful, and has poor thermal properties that increase energy use, increase operating costs, and decrease comfort," Ballard says. "Also, conventional materials like drywall and particleboard are some of the least resilient materials ever invented."

---

This story originally appeared on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings